It is our mission to make steady progress in development and deliver innovative new drugs from Japan to patients.
We are a venture company holding our own drug creation engine and challenging innovative drug creation.
It is not easy to create and deliver to patients candidates for new drugs when the success probability of new drugs is currently said to be not more than one in 30,000. Yet, we are aiming for the success of new drugs based on our history and achievements of protein kinase inhibitor development over 30 years.
Our development products currently under clinical development include one demonstrating efficacy with the “world’s first” mechanism different from existing products and another one indicated for a disease for which treatment drugs are not existent in Japan: this is expected to be the “Japan’s first” very valuable innovative drug.
We will carry out a social mission to provide new drugs with a high level of therapeutic satisfaction and at the same time strive to undertake transparent and reliable management aiming at further growth so that we will keep making ourselves necessary to the society.
Your further understanding and support will be appreciated.
President and CEO Yuichi Hidaka